<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126892</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107ACO01</org_study_id>
    <nct_id>NCT01126892</nct_id>
  </id_info>
  <brief_title>A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase</brief_title>
  <acronym>ENACT</acronym>
  <official_title>An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      A multicenter, open label study of Nilotinib in CML patients PH + with imatininb resistant in
      blast crisis, accelerated phase or chronic phase. The main purpose is evaluate the safety and
      efficacy of Nilotinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the CAMN107A2109 study.</measure>
    <time_frame>between 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate of any durable cytogenetic response and Complete cytogenetic response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate of molecular response every 3 months, until 24th month of treatment or end of study</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To follow loss of HR (after previous confirmed HR for AP and CHR for CP)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Stratum 1:

          1. Currently participating in Novartis study CAMN107A2109

          2. Written signed and dated informed consent prior to any study procedures being
             performed

        Stratum 2:

          1. Male or female

          2. &gt; 18 years

          3. ECOG 0,1,2

          4. ASL/ALT &lt;= 2.5 ULN or &lt;= 5.0 ULN

          5. Alcaline Phosfatase &lt;= 2.5 ULN

          6. Serum Bilirrubin &lt;= 1.5 ULN

          7. Serum Creatinine &lt;= 1.5 ULN or creatinine clearance &gt;=50 ml/min / 24 hours

          8. Serum Lipase &lt;= 1.5 ULN

        Exclusion Criteria:

        Stratum 1 and stratum 2:

          1. Reduction of the cardiac function

          2. Use of Coumadin

          3. Other severe medical concurrent conditions

          4. Treatment with medications that prolonged the QT interval.

          5. Mayor surgery 15 days before the inclusion in the protocol

          6. Pregnant women or lactation

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticlas</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San José, Bogotá, Colombia</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banco Municipal de Sangre</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Venezuela</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=8083</url>
    <description>Results for CAMN107ACO01 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Disease,</keyword>
  <keyword>Resistance,</keyword>
  <keyword>Intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

